It has been suggested that HMGB1 may be a very useful biomarker for the diagnosis and prognosis of hematological malignancies [44]. Our results are consistent with these studies, indicating that HMGB1 is also a therapeutic target in MDS. The gene discussed is HMGB1; the disease is myelodysplastic syndrome.